Logo 1 Logo 2

Clinical Trial Details

Trial ID: L3526
Source ID: NCT01005069
Associated Drug: Dlbs-32
Title: Efficacy of DLBS-32 in Subjects With Type-II Diabetes Mellitus
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG: DLBS-32|DRUG: DLBS-32|DRUG: DLBS-32|DRUG: DLBS-32|DRUG: Placebo capsule
Outcome Measures: Primary: Reduction of venous Fasting Plasma Glucose from baseline, every 2-week interval over 6 weeks of treatment | Secondary: Reduction of 2h-post-prandial plasma glucose from baseline, six weeks|Change of homeostasis model assessment of insulin resistance (HOMA-IR) from baseline, six weeks|Change of high sensitivity C-reactive protein (hs-CRP) from baseline, six weeks|Liver Function, Renal Function, Adverse events, six weeks|Change in HbA1c from baseline, six weeks|Change in lipid profile from baseline, six weeks
Sponsor/Collaborators: Sponsor: Dexa Medica Group
Gender: ALL
Age: ADULT
Phases: PHASE2
Enrollment: 72
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Start Date: 2009-10
Completion Date: 2010-08
Results First Posted:
Last Update Posted: 2010-09-28
Locations: Sanglah Hospital Denpasar, Denpasar, Bali, Indonesia|RSUD Tarakan, Jakarta Pusat, DKI Jakarta, Indonesia
URL: https://clinicaltrials.gov/show/NCT01005069